140 related articles for article (PubMed ID: 36897739)
1. Identification of a PD1/PD-L1 inhibitor by structure-based pharmacophore modelling, virtual screening, molecular docking and biological evaluation.
Choorakottayil Pushkaran A; K K; T AM; Biswas R; Mohan CG
Mol Inform; 2023 Jun; 42(6):e2200254. PubMed ID: 36897739
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, ADMET, and Molecular Dynamics (MD) Simulation of Potential Inhibitors of PD-L1 from the Library of Marine Natural Products.
Luo L; Zhong A; Wang Q; Zheng T
Mar Drugs; 2021 Dec; 20(1):. PubMed ID: 35049884
[TBL] [Abstract][Full Text] [Related]
3. Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach.
Mittal L; Tonk RK; Awasthi A; Asthana S
Arch Biochem Biophys; 2021 Nov; 713():109059. PubMed ID: 34673001
[TBL] [Abstract][Full Text] [Related]
4. Computational design of PD-L1 small molecule inhibitors for cancer therapy.
Chandrasekaran J; Elumalai S; Murugesan V; Kunjiappan S; Pavadai P; Theivendren P
Mol Divers; 2023 Aug; 27(4):1633-1644. PubMed ID: 36006501
[TBL] [Abstract][Full Text] [Related]
5. Liothyronine could block the programmed death-ligand 1 (PDL1) activity: an e-Pharmacophore modeling and virtual screening study.
Pourzardosht N; Hashemi ZS; Mard-Soltani M; Jahangiri A; Rahbar MR; Zakeri A; Mirzajani E; Khalili S
J Recept Signal Transduct Res; 2022 Feb; 42(1):34-42. PubMed ID: 33100099
[TBL] [Abstract][Full Text] [Related]
6. Proposing novel TNFα direct inhibitor Scaffolds using fragment-docking based e-pharmacophore modeling and binary QSAR-based virtual screening protocols pipeline.
Zaka M; Abbasi BH; Durdagi S
J Mol Graph Model; 2018 Oct; 85():111-121. PubMed ID: 30149308
[TBL] [Abstract][Full Text] [Related]
7. Computational discovery of small drug-like compounds as potential inhibitors of PD-1/PD-L1 interactions.
Urban VA; Davidovskii AI; Veresov VG
J Biomol Struct Dyn; 2023 Jul; 41(11):5345-5361. PubMed ID: 35696453
[TBL] [Abstract][Full Text] [Related]
8. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
9. Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction.
Wang F; Ye W; He Y; Zhong H; Zhu Y; Han J; Gong X; Tian Y; Wang Y; Wang S; Ji S; Liu H; Yao X
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835382
[TBL] [Abstract][Full Text] [Related]
10. Structure-based small inhibitors search combined with molecular dynamics driven energies for human programmed cell death-1 (PD-1) protein.
Waqas M; Halim SA; Alsalman A; Khan A; Elkord E; Al-Harrasi A
J Biomol Struct Dyn; 2023; 41(24):14771-14785. PubMed ID: 36927289
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potential inhibitors for stat3: ligand based 3D pharmacophore, virtual screening, molecular docking, dynamic studies and
Lakshmanan K; T K P; K Pai SR; Rajagopal K; Byran G
J Biomol Struct Dyn; 2022; 40(21):11320-11338. PubMed ID: 34463213
[TBL] [Abstract][Full Text] [Related]
12. Kaempferol and Its Glycoside, Kaempferol 7-O-Rhamnoside, Inhibit PD-1/PD-L1 Interaction In Vitro.
Kim JH; Kim YS; Choi JG; Li W; Lee EJ; Park JW; Song J; Chung HS
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32375257
[TBL] [Abstract][Full Text] [Related]
13. In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction.
Lu CH; Chung WM; Tsai CH; Cheng JC; Hsu KC; Tzeng HE
Sci Rep; 2022 Jan; 12(1):303. PubMed ID: 34996924
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
Wang F; Ye W; Wang S; He Y; Zhong H; Wang Y; Zhu Y; Han J; Bing Z; Ji S; Liu H; Yao X
Neoplasia; 2021 Mar; 23(3):281-293. PubMed ID: 33529880
[TBL] [Abstract][Full Text] [Related]
15. Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions.
Kim EH; Kawamoto M; Dharmatti R; Kobatake E; Ito Y; Miyatake H
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455628
[TBL] [Abstract][Full Text] [Related]
16. Development of Novel Small Antitumor Compounds Inhibiting PD-1/PD-L1 Binding.
Akiyama Y; Ashizawa T; Iizuka A; Ando T; Ishikawa Y; Kondou R; Miyata H; Maeda C; Kanematsu A; Sugino T; Yamaguchi K
Anticancer Res; 2022 Nov; 42(11):5233-5247. PubMed ID: 36288869
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore model of immunocheckpoint protein PD-L1 by cosolvent molecular dynamics simulations.
Mejías C; Guirola O
J Mol Graph Model; 2019 Sep; 91():105-111. PubMed ID: 31202914
[TBL] [Abstract][Full Text] [Related]
18. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
Jana S; Singh SK
J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Toxoplasma gondii virulence factor ROP18 competitive inhibitors by virtual screening.
Yin K; Zhao G; Xu C; Qiu X; Wen B; Sun H; Liu G; Liu Y; Zhao Q; Wei Q; Huang B; Yan G; Cao J
Parasit Vectors; 2019 Mar; 12(1):98. PubMed ID: 30867024
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and structure-activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold.
Huang X; Chen H; Dai X; Xu M; Wang K; Feng Z
Bioorg Med Chem Lett; 2021 Nov; 52():128403. PubMed ID: 34610423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
